JP2015513311A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513311A5
JP2015513311A5 JP2014547437A JP2014547437A JP2015513311A5 JP 2015513311 A5 JP2015513311 A5 JP 2015513311A5 JP 2014547437 A JP2014547437 A JP 2014547437A JP 2014547437 A JP2014547437 A JP 2014547437A JP 2015513311 A5 JP2015513311 A5 JP 2015513311A5
Authority
JP
Japan
Prior art keywords
poly
ethylene oxide
mixture
hydrophobic
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014547437A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015513311A (ja
JP6077001B2 (ja
Filing date
Publication date
Priority claimed from US13/324,407 external-priority patent/US8912215B2/en
Application filed filed Critical
Publication of JP2015513311A publication Critical patent/JP2015513311A/ja
Publication of JP2015513311A5 publication Critical patent/JP2015513311A5/ja
Application granted granted Critical
Publication of JP6077001B2 publication Critical patent/JP6077001B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014547437A 2011-12-13 2012-12-13 ラパマイシン組成物 Expired - Fee Related JP6077001B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/324,407 2011-12-13
US13/324,407 US8912215B2 (en) 2011-12-13 2011-12-13 Rapamycin composition
PCT/US2012/069544 WO2013090602A2 (en) 2011-12-13 2012-12-13 Rapamycin composition

Publications (3)

Publication Number Publication Date
JP2015513311A JP2015513311A (ja) 2015-05-07
JP2015513311A5 true JP2015513311A5 (enExample) 2016-01-21
JP6077001B2 JP6077001B2 (ja) 2017-02-08

Family

ID=48572556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014547437A Expired - Fee Related JP6077001B2 (ja) 2011-12-13 2012-12-13 ラパマイシン組成物

Country Status (8)

Country Link
US (1) US8912215B2 (enExample)
EP (1) EP2790700B1 (enExample)
JP (1) JP6077001B2 (enExample)
CN (1) CN104379215B (enExample)
GE (1) GEP201706651B (enExample)
RU (1) RU2557919C1 (enExample)
UA (1) UA115137C2 (enExample)
WO (1) WO2013090602A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
CN105794803B (zh) * 2016-05-06 2018-06-05 重庆大学 Tor蛋白抑制剂抑制植物枯萎病菌、黄萎病菌的新用途
CN105918330B (zh) * 2016-05-24 2018-06-05 重庆大学 雷帕霉素抑制植物早疫病菌的新用途
CN112137961A (zh) * 2020-09-30 2020-12-29 严鹏科 一种雷帕霉素组合物及其制备方法
WO2023145867A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用ポリアルキレンオキシド粒子、医薬用組成物、製剤用組成物及び製剤

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5840319A (en) 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6060518A (en) 1996-08-16 2000-05-09 Supratek Pharma Inc. Polymer compositions for chemotherapy and methods of treatment using the same
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US8257725B2 (en) 1997-09-26 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
JP2006511475A (ja) 2002-09-18 2006-04-06 トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア 脈絡膜新生血管症の抑制方法
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US20070059336A1 (en) 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
AU2006222409A1 (en) 2005-03-08 2006-09-14 Lifecycle Pharma A/S Pharmaceutical compositions comprising sirolimus and/or an analogue thereof
CA2602525A1 (en) 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
US20090053391A1 (en) 2005-12-06 2009-02-26 Ludwig Florian N Method Of Coating A Drug-Releasing Layer Onto A Substrate
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
CN101443004B (zh) 2006-03-23 2013-03-06 参天制药株式会社 用于与血管通透性有关的疾病或病症的制剂
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
GB0625844D0 (en) 2006-12-22 2007-02-07 Daniolabs Ltd The treatment of macular degeneration
US11078262B2 (en) 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
US20090035381A1 (en) 2007-08-01 2009-02-05 Stankus John J Electrospraying method for fabrication of particles and coatings and treatment methods thereof
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
MX2010003364A (es) 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
ATE542525T1 (de) 2007-10-16 2012-02-15 Pharmathen Sa Verbesserte pharmazeutische zusammensetzung mit einem pyrrolidon-antikonvulsivum und verfahren zu seiner herstellung
EP2227085A4 (en) 2007-12-06 2013-10-09 Berg Pharma Llc INGREDIBLE COMPOSITIONS WITH INCREASED BIOLOGICAL AVAILABILITY
US20090291073A1 (en) 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US20100040669A1 (en) 2008-08-12 2010-02-18 Higuchi John W Non-Invasive Ocular Delivery of Rapamycin
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
CA2665956A1 (en) 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
US9101541B2 (en) * 2010-04-28 2015-08-11 Cadila Healthcare Limited Stable solid pharmaceutical matrix compositions of sirolimus

Similar Documents

Publication Publication Date Title
JP2015513311A5 (enExample)
JP2011507946A5 (enExample)
JP2008528653A5 (enExample)
JP2013185119A5 (enExample)
JP2015522001A5 (enExample)
RU2016149734A (ru) Направленно доставляемые терапевтические наночастицы и способы их получения и использования
EP3115428A3 (en) A coating composition and articles made therefrom
AR067365A1 (es) Composiciones detergentes para lavanderia que comprenden polimeros anfifilicos injertados basados en oxidos de polialquileno y vinilesteres
JP2006291180A5 (enExample)
JP2009527608A5 (enExample)
JP2013531102A5 (enExample)
JP2015503560A5 (enExample)
JP2009527505A5 (enExample)
CN106456791A (zh) 眼科用水性组合物
WO2011101259A3 (en) Topcoat composition comprising a polymer containing a repeat unit including a sulfonamide function, photoresist composition containing the same and methods of use
JP2014533756A5 (enExample)
WO2011042463A3 (en) Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
MY161154A (en) Procatalyst composition with alkoxyalkyl 2-propenoate internal electron donor and polymer from same
Rajamalli et al. Glucose-cored poly (aryl ether) dendron based low molecular weight gels: pH controlled morphology and hybrid hydrogel formation
RU2014129612A (ru) Композиция для химико-механического полирования, содержащая поливинилфосфоновую кислоту и ее производные
JP2020518685A5 (enExample)
WO2012138558A3 (en) Asphaltic compositions, filled asphaltic materials, and methods for making asphaltic compositions
JP2016539910A5 (enExample)
JP2017508026A5 (enExample)
RU2018101070A (ru) Лираглутидсодержащий состав длительного действия для лечения заболеваний обмена веществ